M&A Deal Summary

Simulations Plus Acquires Sage Informatics

On August 31, 2005, Simulations Plus acquired software company Sage Informatics

Acquisition Highlights
  • This is Simulations Plus’ 1st transaction in the Software sector.
  • This is Simulations Plus’ 1st transaction in the United States.
  • This is Simulations Plus’ 1st transaction in New Mexico.

M&A Deal Summary
Date 2005-08-31
Target Sage Informatics
Sector Software
Buyer(s) Simulations Plus
Deal Type Add-on Acquisition

Target

Sage Informatics

Santa Fe, New Mexico, United States
Sage Informatics LLC is a provider of software to the pharmaceutical and biotechnology industries.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Simulations Plus

Lancaster, California, United States
Category Company
Founded 1996
Sector Software
Employees192
Revenue 60M USD (2023)
DESCRIPTION

Simulations Plus is a provider of software services to pharmaceutical and biotechnology, industrial chemical, cosmetic, herbicide, and food ingredient industries. Simulations Plus was founded in 1996 and is based in Lancaster, California.

DEAL STATS #
Overall 1 of 4
Sector (Software) 1 of 3
Type (Add-on Acquisition) 1 of 4
State (New Mexico) 1 of 1
Country (United States) 1 of 3
Year (2005) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-01 DILIsym Services

Research Triangle Park, North Carolina, United States

DILIsym Services, Inc. is a provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry. The company spun out of the former Hamner Institutes, acquiring all of the intellectual property, software, documentation, and other materials for the DILIsym® software. The company’s other products include MITOsym® for simulating in vitro mitochondrial function, SimPops™ for evaluating the impact of patient variability, and a new product in development called NAFLDsym™ for the study of nonalcoholic fatty liver disease – a worldwide disease with few available treatment options.

Buy $10M
Mergr

Product

Company

Legal